MedBridgeNZExploring advanced SCI treatments?
FDA-cleared iPSC stem cell therapy for Spinal Cord Injury is now accessible via Medical Tourism China. As your expert medical concierge provider, MedBridgeNZ handles hospital matching and wheelchair logistics so you can focus on care.
Read our complete guide: https://zurl.co/TxpW1
#SpinalCordInjury #iPSCTherapy #MedicalConcierge #MedBridgeNZ #MedicalTourismChina #ChinaMedicalTourism
iPSC Therapy for Spinal Cord Injury in China | Access & Costs
Home > Blog > Advanced Therapies & TechnologyKey Takeaways • Dual Regulatory Clearance: In 2025, XellSmart Biopharmaceutical’s off-the-shelf, allogeneic iPSC-derived neural progenitor cell therapy (XS228) received Investigational New Drug (IND) clearance from both the U.S. FDA and China's NMPA for phase I trials. • Targeted Clinical Window: The current optimal clinical intervention window for this specific iPSC therapy targets patients in the sub-acute phase, specifically 14 to 60 days post-inju